Banerjee, Susana

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

Moore, K., Colombo, N., Scambia, G., Kim, B.-G., Oaknin, A., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A., Sonke, G. S., et al. (2018) · New England Journal of Medicine

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 2,870

ESMO-ESGO Consensus Conference Recommendations on Ovarian Cancer: Pathology and Molecular Biology, Early and Advanced Stages, Borderline Tumours and Recurrent Disease

Colombo, N., Sessa, C., du Bois, A., Ledermann, J., McCluggage, W. G., McNeish, I., Morice, P., Pignata, S., Ray-Coquard, I., Vergote, I., et al. (2019) · Annals of Oncology

Ovarian cancer diagnosis and treatmentBRCA gene mutations in cancer

Cited by 1,197

Overall survival with maintenance Olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1/GOG 3004 trial

DiSilvestro, P., Banerjee, S., Colombo, N., Scambia, G., Kim, B.-G., Oaknin, A., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A., et al. (2023) · Journal of Clinical Oncology

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 511

PARP inhibitors in the Management of Ovarian Cancer: ASCO guideline

Tew, W. P., Lacchetti, C., Ellis, A., Maxian, K., Banerjee, S., Bookman, M., Jones, M. B., Lee, J.-M., Lheureux, S., Liu, J. F., et al. (2020) · Journal of Clinical Oncology

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 315

Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer

George, A., Kaye, S., & Banerjee, S. (2017) · Nature Reviews Clinical Oncology

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 158

Initial efficacy and safety results from ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC).

Banerjee, S. N., Ring, K. L., Van Nieuwenhuysen, E., Fabbro, M., Aghajanian, C., Oaknin, A., Colombo, N., Santin, A., Clamp, A. R., Moore, K. N., et al. (2023) · Journal of Clinical Oncology

Ovarian cancer diagnosis and treatmentOvarian function and disorders

Cited by 38

725MO Phase I study of the combination of the dual RAF/MEK inhibitor VS-6766 and the FAK inhibitor defactinib: Results of efficacy in low grade serous ovarian cancer

Banerjee, S., Grochot, R., Shinde, R., Lima, J., Krebs, M., Rahman, R., Little, M., Tunariu, N., Curcean, A., Badham, H., et al. (2021) · Annals of Oncology

Ovarian cancer diagnosis and treatmentOvarian function and disorders

Cited by 17

Abstract 3476: Mechanistic evaluation of VS-6766 (dual RAF/MEK inhibitor) and defactinib (FAK inhibitor) in low-grade serous ovarian cancer models with correlations to clinical response

Stewart, A. R., Pickard, L., Paranjape, E., Perez, V. S., Chowdhury, S., Lustgarten, S., Coma, S., Pachter, J. A., Carey, M. S., DiMattia, G., et al. (2022) · Cancer Research

Ovarian cancer diagnosis and treatmentMelanoma and MAPK Pathways

Cited by 1